血管内皮生长因子受体1(VEGFR1)检测试剂盒(酶联免疫吸附试验法)
ELISA Kit for Vascular Endothelial Growth Factor Receptor 1 (VEGFR1)
Flt1; Fms-Related Tyrosine Kinase 1; Vascular Permeability Factor Receptor; Fms-like tyrosine kinase 1; Tyrosine-protein kinase receptor FLT
- 编号SEB818Mu
- 物种Mus musculus (Mouse,小鼠) 相同的名称,不同的物种。
- 实验方法双抗夹心
- 反应时长3h
- 检测范围0.156-10ng/mL
- 灵敏度最小可检测剂量小于等于0.058ng/mL.
- 样本类型serum, plasma, tissue homogenates, cell lysates, cell culture supernates and other biological fluids
- 下载 英文说明书 中文说明书
- 规格 48T96T 96T*5 96T*10 96T*100
- 价格 ¥ 1966 ¥ 2808 ¥ 12636 ¥ 23868 ¥ 196560
- 欲了解实际交易价格和更多情况,请与当地经销商联系!
特异性
本试剂盒用于检测血管内皮生长因子受体1(VEGFR1),经检测与其它相似物质无明显交叉反应。
由于受到技术及样本来源的限制,不可能完成对所有相关或相似物质交叉反应检测,因此本试剂盒有可能与未经检测的其它物质有交叉反应。
回收率
分别于定值血清及血浆样本中加入一定量的血管内皮生长因子受体1(VEGFR1)(加标样品),重复测定并计算其均值,回收率为测定值与理论值的比率。
样本 | 回收率范围(%) | 平均回收率(%) |
serum(n=5) | 87-95 | 90 |
EDTA plasma(n=5) | 95-103 | 98 |
heparin plasma(n=5) | 94-105 | 97 |
精密度
精密度用样品测定值的变异系数CV表示。CV(%) = SD/mean×100
批内差:取同批次试剂盒对低、中、高值定值样本进行定量检测,每份样本连续测定20 次,分别计算不同浓度样本的平均值及SD值。
批间差:选取3个不同批次的试剂盒分别对低、中、高值定值样本进行定量测定,每个样本使用同一试剂盒重复测定8次,分别计算不同浓度样本的平均值及SD值。
批内差: CV<10%
批间差: CV<12%
线性
在定值血清及血浆样本内加入适量的血管内皮生长因子受体1(VEGFR1),并倍比稀释成1:2,1:4,1:8,1:16的待测样本,线性范围即为稀释后样本中血管内皮生长因子受体1(VEGFR1)含量的测定值与理论值的比率。
样本 | 1:2 | 1:4 | 1:8 | 1:16 |
serum(n=5) | 98-105% | 93-102% | 86-97% | 91-101% |
EDTA plasma(n=5) | 84-102% | 78-94% | 81-96% | 84-101% |
heparin plasma(n=5) | 78-102% | 79-91% | 87-95% | 97-105% |
稳定性
经测定,试剂盒在有效期内按推荐温度保存,其活性降低率小于5%。
为减小外部因素对试剂盒破坏前后检测值的影响,实验室的环境条件需尽量保持一致,尤其是实验室内温度、湿度及温育条件。其次由同一实验员来进行操作可减少人为误差。
实验流程
1. 实验前标准品、试剂及样本的准备;
2. 加样(标准品及样本)100µL,37°C孵育1小时;
3. 吸弃,加检测溶液A100µL,37°C孵育1小时;
4. 洗板3次;
5. 加检测溶液B100µL,37°C孵育30分钟;
6. 洗板5次;
7. 加TMB底物90µL,37°C孵育10-20分钟;
8. 加终止液50µL,立即450nm读数。
实验原理
将血管内皮生长因子受体1(VEGFR1)抗体包被于96孔微孔板中,制成固相载体,向微孔中分别加入标准品或标本,其中的血管内皮生长因子受体1(VEGFR1)与连接于固相载体上的抗体结合,然后加入生物素化的血管内皮生长因子受体1(VEGFR1)抗体,将未结合的生物素化抗体洗净后,加入HRP标记的亲和素,再次彻底洗涤后加入TMB底物显色。TMB在过氧化物酶的催化下转化成蓝色,并在酸的作用下转化成最终的黄色。颜色的深浅和样品中的血管内皮生长因子受体1(VEGFR1)呈正相关。用酶标仪在450nm波长下测定吸光度(O.D.值),计算样品浓度。
增值服务
相关产品
编号 | 适用物种:Mus musculus (Mouse,小鼠) | 应用(仅供研究使用,不用于临床诊断!) |
RPB818Mu02 | 血管内皮生长因子受体1(VEGFR1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
RPB818Mu01 | 血管内皮生长因子受体1(VEGFR1)重组蛋白 | Positive Control; Immunogen; SDS-PAGE; WB. |
PAB818Mu01 | 血管内皮生长因子受体1(VEGFR1)多克隆抗体 | WB; IHC; ICC; IP. |
PAB818Mu02 | 血管内皮生长因子受体1(VEGFR1)多克隆抗体 | WB; IHC; ICC; IP. |
LAB818Mu71 | 血管内皮生长因子受体1(VEGFR1)多克隆抗体(生物素标记) | WB; IHC; ICC. |
SEB818Mu | 血管内皮生长因子受体1(VEGFR1)检测试剂盒(酶联免疫吸附试验法) | Enzyme-linked immunosorbent assay for Antigen Detection. |
SCB818Mu | 血管内皮生长因子受体1(VEGFR1)检测试剂盒(化学发光免疫分析法) | Chemiluminescent immunoassay for Antigen Detection. |
LMB818Mu | 血管内皮生长因子受体1(VEGFR1)等多因子检测试剂盒(流式荧光发光法) | FLIA Kit for Antigen Detection. |
参考文献
杂志 | 参考文献 |
Clinical cardiology | Growth Differentiation Factor 15 and Coronary Collateral Formation [PubMed: 20014173] |
Microvascular Research | Mutant hypoxia inducible factor-1α improves angiogenesis and tissue perfusion in ischemic rabbit skeletal muscle [PubMed: 20937289] |
Science Alert | Antiangiogenic Activities of Cinnamon, Black and Green Tea Extracts on Experimentally Induced Breast Cancer in Rats [Scialert: Source] |
Acta Biomater | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: an in vitro osteoblast-osteoclast-endothelial cell co-culture study [PubMed: 26689470] |
Naunyn Schmiedebergs Arch Pharmacol | The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis [PubMed: 26269412] |
Acta Biomaterialia | Antioxidant and bone repair properties of quercetin-functionalized hydroxyapatite: An in vitro osteoblast–osteoclast–endothelial cell co-culture study [Pubmed:26689470] |
Journal of Cellular Physiology | A Human 3D In Vitro Model to Assess the Relationship Between Osteoporosis and Disseminationto Bone of Breast Cancer Tumor Cells. [pubmed:27925188] |
Oncotarget | Fasudil attenuates soluble fms-like tyrosine kinase-1 (sFlt-1)-induced hypertension in pregnant mice through RhoA/ROCK pathway. [pubmed:29262624] |
Placenta | Modulating circulating sFlt1 in an animal model of preeclampsia using PAMAM nanoparticles for siRNA delivery. [pubmed:28962687] |
Acta Biomaterialia | Synergistic effect of Si-hydroxyapatite coating and VEGF adsorption on Ti6Al4V-ELI scaffolds for bone regeneration in an osteoporotic bone environment [Pubmed: 30445158] |
Scientific Reports | Association between Upper-airway Surgery and Ameliorative Risk Markers of endothelial function in obstructive Sleep Apnea [Pubmed: 31882827] |
JOURNAL OF DERMATOLOGICAL TREATMENT | Effect of isotretinoin (13-cis-retinoic acid) on levels of soluble VEGF receptors (sVEGFR1, sVEGFR2, sVEGFR3) in patients with acne vulgaris [Pubmed: 32043381] |
FASEB JOURNAL | Cyclin G2 upregulation impairs migration, invasion, and network formation through RNF123/Dvl2/JNK signaling in the trophoblast cell line HTR8/SVneo, a possible … [Pubmed: 33205477] |
Children (Basel) | sFlt-1/PlGF Ratio in Prediction of Short-Term Neonatal Outcome of Small for Gestational Age Neonates [34438609] |
Oxid Med Cell Longev | Reactive Oxygen Species are Essential for Placental Angiogenesis During Early Gestation [Pubmed:35693704] |